14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.055 17 days ( -10.99 % )
Last Price $3.94 0.767 %
High/ Low $3.88 - $4.00 4.39%
Chg 7 Days -0.756 % $3.97 $3.94
Chg 30 Days 36.81 % $2.88 $3.94
Chg 12 mos -56.61 % $9.08 $3.94
Trend - 3 mos 19.91 % Width: 56.71 %
Trend - 12 mos -65.46 % Width: 272.72 %
Pred. range - 3 mos $3.74 - $5.86 -5.03 % - 48.84 %
Pred. range - 12 mos N/A - $1.48 -100.00 % - -62.31 %
Short MA avg 3 mos Buy Apr 23, 2024 - 2 days
Long MA avg 3 mos Buy Apr 01, 2024 - 18 days
Short/Long MA avg 3 mos Buy Apr 03, 2024 - 16 days
Short MA avg 12 mos Sell Apr 23, 2024 - 2 days
Long MA avg 12 mos Buy Mar 27, 2024 - 20 days
Short/Long MA avg 12 mos Buy Feb 16, 2024 - 47 days
Pivot Short Sell Apr 05, 2024 - 14 days
Bollinger Buy Feb 27, 2024 - 41 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria... ALDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT